**Meet the editor**

Professor Ke Xu earned his BSc in Microbiology in 1989 from Nankai University (China) and his PhD in Cell and Molecular Biology in 2001 from the University of Essex (UK). He completed his postdoctoral training at the Institute of Cancer Research (UK) and then carried out his research fellowship at Imperial College London (UK). He joined the Tianjin Lung Cancer Institute at Tianjin

Medical University General Hospital (China) in 2007, studying the mechanism of metastasis and chemoresistance of lung cancer. He also develops novel anticancer drugs. Professor Ke Xu is an active member of American Association of Cancer Research, American Society for Cell Biology, Chinese Anti-Cancer Association, and Chinese Pharmaceutical Association.
